WO2022171098A1 - 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途 - Google Patents
一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途 Download PDFInfo
- Publication number
- WO2022171098A1 WO2022171098A1 PCT/CN2022/075581 CN2022075581W WO2022171098A1 WO 2022171098 A1 WO2022171098 A1 WO 2022171098A1 CN 2022075581 W CN2022075581 W CN 2022075581W WO 2022171098 A1 WO2022171098 A1 WO 2022171098A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- small molecule
- seq
- amino acid
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 276
- 150000003384 small molecules Chemical class 0.000 title claims abstract description 102
- 230000002452 interceptive effect Effects 0.000 title claims abstract description 67
- 239000000758 substrate Substances 0.000 title claims abstract description 12
- 101100233795 Danio rerio krt18 gene Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 135
- 229920001184 polypeptide Polymers 0.000 claims abstract description 82
- 239000003814 drug Substances 0.000 claims abstract description 41
- 229940079593 drug Drugs 0.000 claims abstract description 34
- 208000006011 Stroke Diseases 0.000 claims abstract description 29
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 14
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 8
- 206010003805 Autism Diseases 0.000 claims abstract description 8
- 208000020706 Autistic disease Diseases 0.000 claims abstract description 8
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 8
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 claims abstract description 8
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 8
- 208000030886 Traumatic Brain injury Diseases 0.000 claims abstract description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 8
- 230000007246 mechanism Effects 0.000 claims abstract description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 8
- 208000020431 spinal cord injury Diseases 0.000 claims abstract description 8
- 230000009529 traumatic brain injury Effects 0.000 claims abstract description 8
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims abstract description 7
- 208000009973 brain hypoxia - ischemia Diseases 0.000 claims abstract description 7
- 208000033300 perinatal asphyxia Diseases 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 102100038587 Death-associated protein kinase 1 Human genes 0.000 claims abstract 3
- 101000956145 Homo sapiens Death-associated protein kinase 1 Proteins 0.000 claims abstract 3
- 229940024606 amino acid Drugs 0.000 claims description 39
- 235000001014 amino acid Nutrition 0.000 claims description 38
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 31
- 230000004927 fusion Effects 0.000 claims description 29
- -1 polypropylene Fumarate Polymers 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 22
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 20
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 20
- 230000000149 penetrating effect Effects 0.000 claims description 19
- 230000002441 reversible effect Effects 0.000 claims description 17
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 14
- 230000004770 neurodegeneration Effects 0.000 claims description 13
- 230000037361 pathway Effects 0.000 claims description 13
- 239000003146 anticoagulant agent Substances 0.000 claims description 11
- 230000026731 phosphorylation Effects 0.000 claims description 11
- 238000006366 phosphorylation reaction Methods 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 8
- 229920000669 heparin Polymers 0.000 claims description 8
- 150000008575 L-amino acids Chemical group 0.000 claims description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 6
- 238000007363 ring formation reaction Methods 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 5
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 5
- 229940127219 anticoagulant drug Drugs 0.000 claims description 5
- 229940127218 antiplatelet drug Drugs 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 4
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 4
- 108010007267 Hirudins Proteins 0.000 claims description 4
- 102000007625 Hirudins Human genes 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- AKGGYBADQZYZPD-UHFFFAOYSA-N benzylacetone Chemical compound CC(=O)CCC1=CC=CC=C1 AKGGYBADQZYZPD-UHFFFAOYSA-N 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 4
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960000288 dabigatran etexilate Drugs 0.000 claims description 4
- 229960001912 dicoumarol Drugs 0.000 claims description 4
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims description 4
- 229960001318 fondaparinux Drugs 0.000 claims description 4
- 229940006607 hirudin Drugs 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 230000002461 excitatory amino acid Effects 0.000 claims description 3
- 239000003257 excitatory amino acid Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 230000026683 transduction Effects 0.000 claims description 3
- 238000010361 transduction Methods 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- KQBXYYMELBQTFL-UHFFFAOYSA-N 2,3-dihydrocyclopenta[a]naphthalen-1-one Chemical compound C1=CC=CC2=C3C(=O)CCC3=CC=C21 KQBXYYMELBQTFL-UHFFFAOYSA-N 0.000 claims description 2
- VARKFMHUVKZOHE-UHFFFAOYSA-N 2-(butan-2-ylamino)-2-oxoacetic acid Chemical compound CCC(C)NC(=O)C(O)=O VARKFMHUVKZOHE-UHFFFAOYSA-N 0.000 claims description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims description 2
- WFFZGYRTVIPBFN-UHFFFAOYSA-N 3h-indene-1,2-dione Chemical compound C1=CC=C2C(=O)C(=O)CC2=C1 WFFZGYRTVIPBFN-UHFFFAOYSA-N 0.000 claims description 2
- KYWCWBXGRWWINE-UHFFFAOYSA-N 4-methoxy-N1,N3-bis(3-pyridinylmethyl)benzene-1,3-dicarboxamide Chemical compound COC1=CC=C(C(=O)NCC=2C=NC=CC=2)C=C1C(=O)NCC1=CC=CN=C1 KYWCWBXGRWWINE-UHFFFAOYSA-N 0.000 claims description 2
- 108010058207 Anistreplase Proteins 0.000 claims description 2
- 102000004411 Antithrombin III Human genes 0.000 claims description 2
- 108090000935 Antithrombin III Proteins 0.000 claims description 2
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims description 2
- 239000005465 B01AC22 - Prasugrel Substances 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- ULSLJYXHZDTLQK-UHFFFAOYSA-N Coumatetralyl Chemical compound C1=CC=CC2=C1OC(=O)C(C1C3=CC=CC=C3CCC1)=C2O ULSLJYXHZDTLQK-UHFFFAOYSA-N 0.000 claims description 2
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 2
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 claims description 2
- 108010056764 Eptifibatide Proteins 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- 108010071289 Factor XIII Proteins 0.000 claims description 2
- 101710196208 Fibrinolytic enzyme Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 239000004642 Polyimide Substances 0.000 claims description 2
- 108010023197 Streptokinase Proteins 0.000 claims description 2
- 108010039185 Tenecteplase Proteins 0.000 claims description 2
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims description 2
- 244000250129 Trigonella foenum graecum Species 0.000 claims description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 claims description 2
- 229960000446 abciximab Drugs 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 229960002054 acenocoumarol Drugs 0.000 claims description 2
- VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- 229960003318 alteplase Drugs 0.000 claims description 2
- 229960000983 anistreplase Drugs 0.000 claims description 2
- 229960005348 antithrombin iii Drugs 0.000 claims description 2
- 229960003886 apixaban Drugs 0.000 claims description 2
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims description 2
- 229960003856 argatroban Drugs 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960003616 bemiparin Drugs 0.000 claims description 2
- 229960002890 beraprost Drugs 0.000 claims description 2
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 claims description 2
- 229950011103 betrixaban Drugs 0.000 claims description 2
- XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 claims description 2
- 230000006287 biotinylation Effects 0.000 claims description 2
- 238000007413 biotinylation Methods 0.000 claims description 2
- 108010055460 bivalirudin Proteins 0.000 claims description 2
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 claims description 2
- 229960001500 bivalirudin Drugs 0.000 claims description 2
- 229960004105 carbasalate calcium Drugs 0.000 claims description 2
- 210000004671 cell-free system Anatomy 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229960004588 cilostazol Drugs 0.000 claims description 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 claims description 2
- 229960003009 clopidogrel Drugs 0.000 claims description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 229960000956 coumarin Drugs 0.000 claims description 2
- 235000001671 coumarin Nutrition 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 229960004969 dalteparin Drugs 0.000 claims description 2
- 229960004120 defibrotide Drugs 0.000 claims description 2
- 229940051593 dermatan sulfate Drugs 0.000 claims description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 2
- 229960002768 dipyridamole Drugs 0.000 claims description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims description 2
- 229960000622 edoxaban Drugs 0.000 claims description 2
- 229960000610 enoxaparin Drugs 0.000 claims description 2
- 229960004468 eptifibatide Drugs 0.000 claims description 2
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 238000001215 fluorescent labelling Methods 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229960002240 iloprost Drugs 0.000 claims description 2
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 229960003422 indobufen Drugs 0.000 claims description 2
- AYDXAULLCROVIT-UHFFFAOYSA-N indobufen Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1N1C(=O)C2=CC=CC=C2C1 AYDXAULLCROVIT-UHFFFAOYSA-N 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007919 intrasynovial administration Methods 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 230000029226 lipidation Effects 0.000 claims description 2
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 2
- 229960002137 melagatran Drugs 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 238000007069 methylation reaction Methods 0.000 claims description 2
- 108010075698 monteplase Proteins 0.000 claims description 2
- 229950005805 monteplase Drugs 0.000 claims description 2
- 230000007498 myristoylation Effects 0.000 claims description 2
- 229960000899 nadroparin Drugs 0.000 claims description 2
- 230000026792 palmitoylation Effects 0.000 claims description 2
- 229960004762 parnaparin Drugs 0.000 claims description 2
- 230000006320 pegylation Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229960001006 picotamide Drugs 0.000 claims description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 239000000622 polydioxanone Substances 0.000 claims description 2
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims description 2
- 239000004633 polyglycolic acid Substances 0.000 claims description 2
- 229920001721 polyimide Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229920001299 polypropylene fumarate Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229960004197 prasugrel Drugs 0.000 claims description 2
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 229960002917 reteplase Drugs 0.000 claims description 2
- 108010051412 reteplase Proteins 0.000 claims description 2
- 229960001148 rivaroxaban Drugs 0.000 claims description 2
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229960002055 saruplase Drugs 0.000 claims description 2
- 108010073863 saruplase Proteins 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229960005202 streptokinase Drugs 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 229960000216 tenecteplase Drugs 0.000 claims description 2
- 238000011191 terminal modification Methods 0.000 claims description 2
- 229960002528 ticagrelor Drugs 0.000 claims description 2
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 claims description 2
- 229960005001 ticlopidine Drugs 0.000 claims description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims description 2
- 229960005062 tinzaparin Drugs 0.000 claims description 2
- 229960003425 tirofiban Drugs 0.000 claims description 2
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 claims description 2
- 238000011269 treatment regimen Methods 0.000 claims description 2
- 229960005032 treprostinil Drugs 0.000 claims description 2
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims description 2
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims description 2
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 claims description 2
- 229960005356 urokinase Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 238000006664 bond formation reaction Methods 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 abstract description 15
- 238000012827 research and development Methods 0.000 abstract description 2
- 108010031042 Death-Associated Protein Kinases Proteins 0.000 description 27
- 102000005721 Death-Associated Protein Kinases Human genes 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 241000700159 Rattus Species 0.000 description 24
- 230000010410 reperfusion Effects 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 19
- 230000030833 cell death Effects 0.000 description 17
- 229930195712 glutamate Natural products 0.000 description 16
- 101001026870 Homo sapiens Serine/threonine-protein kinase D1 Proteins 0.000 description 15
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 13
- 210000001168 carotid artery common Anatomy 0.000 description 13
- 206010008118 cerebral infarction Diseases 0.000 description 13
- 229940118019 malondialdehyde Drugs 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 201000006474 Brain Ischemia Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 206010008120 Cerebral ischaemia Diseases 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 230000000324 neuroprotective effect Effects 0.000 description 9
- 230000001052 transient effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 230000002146 bilateral effect Effects 0.000 description 7
- 210000000269 carotid artery external Anatomy 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 238000000692 Student's t-test Methods 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 210000004004 carotid artery internal Anatomy 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000016273 neuron death Effects 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 108010061269 protein kinase D Proteins 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000004072 Beclin-1 Human genes 0.000 description 5
- 108090000524 Beclin-1 Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 238000012453 sprague-dawley rat model Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010048962 Brain oedema Diseases 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 102000011727 Caspases Human genes 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- XLIJUKVKOIMPKW-BTVCFUMJSA-N [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XLIJUKVKOIMPKW-BTVCFUMJSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000004900 autophagic degradation Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 208000006752 brain edema Diseases 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 210000003618 cortical neuron Anatomy 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 4
- 239000004090 neuroprotective agent Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010048964 Carotid artery occlusion Diseases 0.000 description 3
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 3
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 3
- 208000028389 Nerve injury Diseases 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 102000038030 PI3Ks Human genes 0.000 description 3
- 108091008611 Protein Kinase B Proteins 0.000 description 3
- 102000003861 Ribosomal protein S6 Human genes 0.000 description 3
- 108090000221 Ribosomal protein S6 Proteins 0.000 description 3
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 3
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000010523 cascade reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000007946 glucose deprivation Effects 0.000 description 3
- 210000004295 hippocampal neuron Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000037906 ischaemic injury Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 230000008764 nerve damage Effects 0.000 description 3
- 230000009223 neuronal apoptosis Effects 0.000 description 3
- 230000004112 neuroprotection Effects 0.000 description 3
- 229960001227 oxiracetam Drugs 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 208000030151 polycystic kidney disease 3 with or without polycystic liver disease Diseases 0.000 description 3
- 210000002243 primary neuron Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010825 rotarod performance test Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102100038606 Death-associated protein kinase 3 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000956149 Homo sapiens Death-associated protein kinase 3 Proteins 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 230000010102 embolization Effects 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 231100000063 excitotoxicity Toxicity 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000011302 passive avoidance test Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 239000007845 reactive nitrogen species Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000009861 stroke prevention Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- LNOBZXNCABUBKK-UHFFFAOYSA-N 2,3,5-triphenyltetrazolium Chemical compound C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 LNOBZXNCABUBKK-UHFFFAOYSA-N 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101100276977 Caenorhabditis elegans dapk-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000047174 Disks Large Homolog 4 Human genes 0.000 description 1
- 108700019745 Disks Large Homolog 4 Proteins 0.000 description 1
- 101100339887 Drosophila melanogaster Hsp27 gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101150096895 HSPB1 gene Proteins 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000005640 Myosin Type II Human genes 0.000 description 1
- 108010045128 Myosin Type II Proteins 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010050081 Neonatal hypoxia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000042866 PKD family Human genes 0.000 description 1
- 108091082284 PKD family Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229930184420 clematichinenoside Natural products 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007916 intrasternal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000012316 non-parametric ANOVA Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Definitions
- the invention relates to the field of research and development of small molecule polypeptide drugs, in particular to an artificial small molecule interfering peptide of DAPK1 phosphorylation substrate and its pharmaceutical application.
- Stroke also known as "stroke”
- stroke is a group of acute cerebrovascular diseases with sudden onset and focal neurological deficit as common features. It has the characteristics of high recurrence rate, high medical care cost and many complications, but low awareness rate, low treatment rate and low control rate.
- stroke is the second leading cause of death in the world and the first cause of adult disability, seriously affecting human health and quality of life, and causing a serious psychological burden to the patient's family and society. and economic losses.
- stroke is the leading cause of death and disability among adults in my country, and the number of deaths accounts for about 1/3 of the global cerebrovascular disease deaths. The number of surviving patients is now 12.42 million, and the incidence rate is also rising rapidly and showing a younger trend.
- Stroke is divided into ischemic and hemorrhagic. Among them, ischemic stroke accounts for about 87%. It is a serious neurological disease caused by the interruption of blood flow caused by thrombosis or embolism. The patient will suddenly appear paralysis. , language impairment or vision loss or even death.
- the current effective treatment is thrombolytic therapy using recombinant tissue plasminogen activator (rtPA).
- rtPA tissue plasminogen activator
- due to the fact that the effective treatment time window for stroke is too short, the actual operation time cannot be controlled, and it is also faced with problems such as blood reperfusion injury and easy induction of intracranial hemorrhage. At present, only about 5% of patients can apply thrombolytic therapy, and most patients only Symptomatic and supportive treatment is available.
- neuroprotective agents to protect normal nerve cells and rescue undead nerve tissue can reduce the size of cerebral infarction and avoid complications of thrombolytic or anticoagulant therapy.
- Early treatment is possible, and neuroprotective agents can be used for hemorrhagic stroke, so its therapeutic effect and prospects are expected, and it is a recent research focus of stroke treatment.
- laboratories around the world have developed more than 1,000 small-molecule compounds for ischemic stroke neuroprotective agents, and more than 200 clinical trials have been carried out. So far, there is no generally recognized neuroprotective agent, which needs to be continuously developed. It is extremely important for the effective treatment of stroke to explore new therapeutic methods to reduce nerve cell death.
- DAPK1 Death Associated Protein Kinase 1
- DAPK1-NR2B pathway, DAPK1-DANGER pathway, DAPK1-p53 pathway and DAPK1-Tau pathway are all involved in hypoxia and hypoglycemia-induced cell death, and blocking these in acute treatment of animal ischemia and hypoxia model Cascade can effectively reduce neuronal death, but no effective drug has been successfully developed as a clinical treatment based on this so far, so it is necessary to develop more drugs for ischemic stroke.
- Polypeptide generally refers to a small molecular protein containing less than 100 amino acids. It has the incomparable advantages of small molecular compounds and macromolecular drugs such as proteins: like small molecular compounds, it does not require digestion, and can be directly injected and absorbed quickly. Almost 100% absorption and utilization without energy consumption, does not cause gastrointestinal functional burden and metabolic burden, can be absorbed as a carrier, and has the same molecular cognition as macromolecules, obvious structure-activity relationship, significant pharmacodynamics, and small drug dosage , strong biological activity, low toxicity, low or no side effects, no accumulation. It is an important direction of drug development in recent years.
- the present invention develops ischemic stroke drugs in the direction of small molecule polypeptide drugs, and provides a development method for ischemic stroke drugs according to the research results, and a small molecule polypeptide, Its intermediate product (gene sequence, expression vector) and its pharmaceutical application in preventing and treating ischemic stroke.
- an artificial small molecule interfering peptide of DAPK1 phosphorylation substrate is characterized in that, its amino acid sequence is such as SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4 or SEQ ID NO.5 is shown.
- an artificial small molecule interfering peptide of a DAPK1 phosphorylation substrate characterized in that it has the amino acid motif shown in the following (A) or (B):
- each X can be independently selected from any amino acid or no amino acid
- X1 is a polar amino acid selected from asparagine (N), cysteine (C), glutamine (Q), serine (S) or threonine (T)
- X 2 is a non-polar amino acid selected from alanine (A), isoleucine (I), leucine (L), methionine (M) and valine (V);
- R/K means that arginine (R) or lysine (K) can be optionally used at this position;
- S/T/A means that serine (S), threonine (T) or alanine (A) can be optionally used at this position;
- the amino acid sequence of the artificial small molecule interfering peptide is also different from at least one of the amino acid sequences shown in SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3 by no more than 2 amino acids, i.e. Has at least 85% consistency.
- the artificial small molecule interfering peptide according to embodiment 2 its amino acid sequence is as shown in any of SEQ ID NO.6-54.
- the artificial small molecule interference peptidomimetic is a stapled peptide or a cyclic peptide, such as: head-to-tail ring formation (amide bond), side chain ring formation, thioester bond ring formation, lactone bond Cycling, oxidation between Se-Cys and Se-Cys, or cyclic peptides with disulfide bonds.
- the D-type retro-inverse peptide of the artificial small-molecule interfering peptide is the highest in the artificial small-molecule interfering peptide compared with the artificial small-molecule interfering peptide.
- Each L-amino acid residue is replaced by its corresponding D-type amino acid, and its amino acid sequence is reversed while the original spatial direction and chirality of its side chain are the same as those of the artificial small molecule interfering peptide, that is, keep the same as the artificial small molecule interfering peptide.
- Small molecules interfere with peptide-like side chain topology.
- a derivative peptide of the artificial small molecule interfering peptide according to any one of embodiments 1-3 characterized in that, it is any one or more amino acids in the artificial small molecule interfering peptide according to any one of embodiments 1-3. It is obtained by replacing it with its corresponding D-type amino acid or high amino acid.
- a polypeptide characterized in that, two or more small molecular peptides are polymerized in parallel in the same direction, wherein the C-terminus of each small molecular peptide is free, and the N-termini of all small molecular peptides are gathered together for use. in connection with a delivery vehicle;
- the small molecule peptide is selected from the artificial small molecule interfering peptide described in any one of Embodiments 1-3, the inverse polypeptide described in Embodiment 5, the D-type retro-inverse peptide described in Embodiment 6, or the described in Embodiment 7 derived peptides.
- a fusion polypeptide characterized in that it is formed by merging one or more delivery vectors at the N-terminus or C-terminus of the small molecule peptide;
- the small molecule peptide is selected from the artificial small molecule interfering peptide described in any one of Embodiments 1-3, the inverse polypeptide described in Embodiment 5, the D-type retro-inverse peptide described in Embodiment 6, or the described in Embodiment 7 derived peptides.
- the membrane-penetrating peptide is selected from cationic cell-penetrating peptide, amphiphilic cell-penetrating peptide, hydrophobic cell-penetrating peptide or synthetic cell-penetrating peptide;
- the high molecular polymer is selected from polyethylene glycol (PEG), polylactic acid, poly Lactide-co-Glycolide, polyglycolic acid, polycaprolactone, polyethylene oxide, polydioxanone, polypropylene Fumarate, trimethylene carbonate, polyester amide ethylene oxide, ester amide, ⁇ -hydroxybenzoate, ⁇ -hydroxy acid, polyhydroxyalkanoic acid, polyhydroxybutyric acid, polyimide carbon acid salt, polyurethane, polyanhydride, hyaluronic acid, chitosan, cellulose, gelatin, collagen.
- PEG polyethylene glycol
- polylactic acid poly Lactide-co-Glycolide
- polyglycolic acid polycaprolactone
- polyethylene oxide polydioxanone
- polypropylene Fumarate trimethylene carbonate
- fusion polypeptide according to embodiment 10 is characterized in that,
- the cationic cell-penetrating peptide is selected from the group consisting of amino acid sequences shown in Seq.ID No.55 to Seq.ID No.72;
- amphiphilic cell-penetrating peptide is selected from the group consisting of amino acid sequences shown in Seq.ID No.73 to Seq.ID No.81;
- hydrophobic cell-penetrating peptide is selected from the group consisting of amino acid sequences shown in Seq.ID No.82 to Seq.ID No.85;
- the synthetic cell-penetrating peptide has the amino acid sequence shown in Seq.ID No.86.
- An artificially prepared nucleic acid molecule characterized in that it encodes a small molecule polypeptide, and the small molecule peptide is selected from the artificial small molecule interfering peptides described in any one of Embodiments 1-3, and the anti-interfering peptides described in Embodiment 5. to the polypeptide.
- An expression vector characterized in that the nucleic acid molecule of 14 is loaded.
- An expression system characterized in that it is a cell line or cell-free system expression system, comprising the vector described in Embodiment 15.
- An expression product characterized in that it is expressed by the expression system described in embodiment 14, and its main component is a small molecule polypeptide; the small molecule peptide is selected from the artificial small molecule described in any one of embodiments 1-3 Interfering peptide, the reverse polypeptide described in Example 5.
- a medicine characterized in that it contains a polypeptide molecule and pharmaceutically acceptable impurities, adjuvants, solvents, protective agents, adjuvants, carriers and/or excipients; wherein the polypeptide molecule is:
- the small molecule peptides are selected from the artificial small molecule interfering peptides described in any one of Embodiments 1-3, the reverse polypeptide described in Embodiment 5, and the D described in Embodiment 6. type retro-inverse peptide, or the derivative peptide described in Example 7; the modification refers to one or more of the following:
- N-terminal, C-terminal modification, labeling cyclization, lipidation, N-methylation, myristoylation and palmitoylation, glycosylation, biotinylation, PEGylation, fluorescent labeling.
- the dosage form is: inhalation aerosol, oral dosage, intravenous administration, intraarterial administration, intracranial administration, intraperitoneal administration, intranasal administration , Intramuscular administration, subcutaneous administration, intrasynovial (cavity) administration, intrasternal administration, and intravertebral administration preparations.
- small molecule peptides characterized in that, the small molecule peptides are selected from the artificial small molecule interfering peptides described in any one of Embodiments 1-3, the reverse polypeptide described in Embodiment 5, Embodiment 6 The D-type retro-inverse peptide, or the derivative peptide described in Example 7;
- the pharmaceutical use refers to the preparation of drugs for the treatment or prevention of diseases related to the mechanism of excitatory amino acid toxicity, including but not limited to stroke, traumatic brain injury, spinal cord injury, and neonatal hypoxic-ischemic encephalopathy. , neurodegenerative diseases, depression, autism;
- the neurodegenerative disease refers to multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease or Huntington's disease.
- small molecule peptides characterized in that, the small molecule peptides are selected from the artificial small molecule interfering peptides described in any one of Embodiments 1-3, the reverse polypeptide described in Embodiment 5, and Embodiment 6
- the pharmaceutical use refers to the preparation of a drug for the treatment or prevention of physiological abnormalities related to the DAPK1-PKD1 pathway, including but not limited to brain diseases Stroke, traumatic brain injury, spinal cord injury, neonatal hypoxic-ischemic encephalopathy, neurodegenerative diseases, depression, autism;
- the neurodegenerative disease refers to multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease or Huntington's disease.
- a drug combination characterized in that it comprises the drug of embodiment 18 or 19 and an anticoagulant or an antiplatelet drug;
- the medicine of embodiment 18 or 19 and the anticoagulant or antiplatelet medicine are packaged together in a single dose, a single daily dose or a course of treatment dose as a unit;
- the anticoagulant drugs refer to acenocoumarin, 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin (coumarin), dicoumarin fenugreek, dicoumarin ethyl ester, phenprocoumarin, benzylacetone coumarin, benzoindanone, indanedione, ticlocoumarol, bemiparin, sertoparin sodium, dalteparin, Noraparin, Nadroparin, Parnaparin, Revitaparin, Tinzaparin, Fondaparinux, Idaparinux, Danaparin, Sulodide, Dermatan sulfate, Apixaban, Betrixaban, Duxaban, Omisaban, Rivaroxaban, Hirudin, Bivalirudin, Recombinant Hirudin, Desiludin Hirudin, Argatroban, Dabigatran etexilate, Melagatran,
- the antiplatelet drugs refer to clopidogrel, ticagrelor, prasugrel, dipyridamole, cilostazol, ticlopidine, eptifibatide, aspirin, abciximab, tiro Fiban, beraprost, cycloprostaglandin, iloprost, treprostinil, aloprin, carbasalate calcium, indobufen, triflusalic acid, picotamide, trutrol class, cloromonte, destazol, or a combination thereof.
- small molecule peptides for the treatment of diseases, characterized in that the small molecule peptides are selected from the artificial small molecule interfering peptides described in any one of Embodiments 1-3, the reverse polypeptides described in Embodiment 5, the examples The D-type retro-inverse peptide described in 6, or the derivative peptide described in Example 7;
- the administration amount is from 0.001 mg/kg body weight to 50 mg/kg; the concentration of the small molecule peptides described herein can vary widely, and depends on the chosen administration mode and the subject's body weight, age, sex, etc. make a selection;
- the preferred dosage range is from 0.01 mg/kg body weight to 50 mg/kg;
- a further preferred dosage range is from 0.1 mg/kg body weight to 10 mg/kg;
- the diseases include, but are not limited to, stroke, traumatic brain injury, spinal cord injury, neonatal hypoxic-ischemic encephalopathy, neurodegenerative diseases, depression, and autism;
- the neurodegenerative disease refers to multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease or Huntington's disease.
- DAPK1 protein kinase D1
- PPD1 protein kinase D1
- Apoptosis Signal-regulated Kinase 1 (ASK1) binding and its downstream-induced phosphorylation of c-N-terminal kinase (JNK) are critical, and studies have also shown that ASK1-dependent JNK signaling The pathway mediates both caspase-dependent apoptosis and caspase-independent necrosis of cell death after ischemia.
- PKD1 protein kinase D1 belongs to the protein kinase D (Protain kinase D, PKD) family, which is a kind of protein kinase D (Protain kinase D, PKD) family in cells.
- PKD1 Widely expressed cytoplasmic serine-threonine kinase with unique structural, enzymatic and regulatory properties.
- the PKD family has three members, PKD1, PKD2, and PKD3. Compared with PKD2 and PKD3, PKD1 is the most studied. It is generally believed that PKD2 and PKD1 are similar in distribution and function, while PKD3 mainly reciprocates between the cytoplasm and the nucleus. In the domain, there is a high degree of homology among the three members of PKD.
- PKD has been reported to be involved in a variety of cellular functions, including Golgi organization as well as plasma membrane-guided trafficking, metastasis, immune response, apoptosis, and cell proliferation (doi: 10.1152/physiol.00037.2010, Advances in Physiological Sciences 2011 vol. 42 Issue 5).
- the small molecule polypeptide drug developed by the present invention has been applied to the in vitro oxidative stress injury model and the whole animal stroke model.
- the experimental data proves that the small molecule polypeptide drug developed by the present invention has significant effects in the glutamate cell apoptosis model. It can effectively inhibit the damage of primary neuronal cells caused by oxygen and glucose deprivation, that is, it can effectively interfere with the DAPK1-PKD1 pathway of neurons, inhibit the downstream neuronal caspase-dependent apoptosis and Signaling of caspase-independent necrosis reduces brain damage after ischemic stroke.
- the small molecule interfering peptides developed in the present invention can be used to prepare medicines for the treatment or prevention of diseases related to the mechanism of excitatory amino acid toxicity, including but not limited to stroke, traumatic brain injury, spinal cord injury, and neonatal hypoxia Ischemic encephalopathy, neurodegenerative diseases (eg, multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease), depression, autism.
- diseases related to the mechanism of excitatory amino acid toxicity including but not limited to stroke, traumatic brain injury, spinal cord injury, and neonatal hypoxia Ischemic encephalopathy, neurodegenerative diseases (eg, multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease), depression, autism.
- diseases related to the mechanism of excitatory amino acid toxicity including but not limited to stroke, traumatic brain injury, spinal cord injury, and neonatal hypoxia Ischemic encephalopathy, neurodegenerative diseases
- natural amino acid refers to the 20 conventional amino acids that can be automatically produced in the body, generally L-type amino acids.
- D-type amino acid refers to an amino acid that is symmetrical in structure to an L-type amino acid, and is an amino acid artificially synthesized by D-type glyceraldehyde. With the exception of glycine, all amino acids have stereoisomers (mirror images of their structures).
- high amino acids also known as long-chain amino acids: derivatives of a class of natural amino acids, a methylene group (CH 2 ) is inserted into the natural amino acid carbon skeleton next to the carboxyl group to extend The carbon chain of amino acids; used to improve the biological activity and biological stability of polypeptides.
- polypeptide and “artificial small molecule polypeptide” are specially defined or explained, they all have the characteristics of amino acid sequence generally understood in the art, for example, the amino acid residue is a natural L-type amino acid, and the left end of the amino acid sequence is an ⁇ -NH 2 group, that is, The left is the N-terminus, the right is the ⁇ -COOH group and the right is the C-terminus.
- inverted polypeptide means that the sequence of amino acids in the peptide chain is changed from C-terminal to N-terminal compared to the original peptide chain.
- reverse polypeptide of N SGVRRRRLSNVSL C is: N LSVNSLRRRRVGS C
- D-type retro-inverse peptide that is, compared with the original L-amino acid peptide composed of natural L-type amino acids, is obtained by replacing each L-amino acid residue in the original L-amino acid peptide with its corresponding D-type amino acid, Its amino acid sequence is reversed while the original spatial orientation and chirality of its side chain are the same as the original L-amino acid peptide, that is, the side chain topology similar to that of the original L-amino acid peptide is maintained.
- Figure 1 shows the identification and quantitative analysis results of fusion polypeptide RvTAT-PKD-S205 of the present invention, wherein
- Figure 2 Shows the effect of fusion polypeptides of the invention on glutamate-induced HT22 cell death, wherein
- HT22 cells containing five different concentrations of RvTAT-PKD-S205 from 0-1600 nM were exposed to 6 mM glutamate (GLUT) for 24 h at 37 degrees Celsius, and the cytotoxicity of the cells was determined by MTT assay.
- the RvTAT-PKD-S205 group at a concentration of 0 nM was used as a control.
- Cell death rate (%) 100% x (control OD - dosing OD)/control OD.
- FIG. 3 Shows the neuroprotective effect of the fusion polypeptide of the present invention in the neuronal oxygen-glucose deprivation/reperfusion model (OGD/R) and the comparison of different fusion polypeptides, wherein
- Fig. 5. shows the neuroprotective effect of fusion polypeptide of the present invention on whole animal transient middle cerebral artery occlusion and reperfusion model, wherein:
- Figure 6 Shows the neuroprotective effect of the fusion polypeptide of the present invention on transient global cerebral ischemia-reperfusion whole animal stroke model, wherein (A) the timetable and sampling scheme of the experiment C57BL/6 mouse bilateral carotid arteries twice 20 min of occlusion with reperfusion (tBCCAO/R) and treated with 7 mg/2 ml/kg RvTAT-PKD-S205 or the same volume of normal saline via tail vein 3 h after tBCCAO, passive avoidance of the Y-maze after 24 h of reperfusion Laboratory tests, as well as determination of MDA, and determination of water content in the brain;
- the inventors put forward a hypothesis on the effect of DAPK1-PKD1 pathway on ischemic nerve injury, and selected amino acids between positions 197 and 210 of protein kinase D to form a small molecule interfering peptide (PKD-S205), as shown in Table 1 Seq ID No. 1 shown.
- DAPK1 Since DAPK1 has a variety of phosphorylated specific substrates, in the signaling cascade triggered by the stress response, in addition to interacting with PKD1, DAPK1 also phosphorylates myosin II regulatory light chain (MLC) and activates Myosin, leading to vacuolization of the cell membrane. DAPK1 phosphorylates serine (Ser235) at position 235 of ribosomal protein S6 (rSP6), which reduces the translation rate of the protein.
- MLC myosin II regulatory light chain
- DAPK1 phosphorylates threonine (Thr119) at position 119 of the BH3 domain in the autophagy effector protein Beclin 1 (BECN1), which promotes Beclin 1 and B-cell lymphoma-extralarge (Bcl-XL) dissociation to induce autophagy.
- DAPK1 phosphorylates threonine at position 299 of Zipper-interacting protein kinase (ZIPK) to change its intracellular localization and promote cell death.
- ZIPK Zipper-interacting protein kinase
- the present invention also designs interfering peptides for the phosphorylation sites of these phosphorylation substrates of DAPK1, such as SEQ ID NO. 2-6 in Table 1.
- CPPs Cell penetrating peptides
- Permeabilization and other mechanisms transport macromolecules such as protein, RNA, DNA, etc. into cells to exert their effector functions. After entering cells, they can be decomposed normally, so they have good biocompatibility and low cytotoxicity.
- Penetrating peptides that are well known in the art can be used in the present invention, such as those listed in the following table:
- the reverse sequence TAT (RRRQRRKKRG) of TAT (47-57) is selected as the penetrating peptide to be linked with the small molecule interfering peptide developed by the present invention to form a fusion molecule, and the penetrating peptide is linked to the small molecule interfering peptide.
- the amino acid sequence of the partial fusion polypeptide of the present invention is as follows.
- Seq ID No.93 RKPERRRLKTTRLRRRQRRKKRG ZIPK-T299-RvTAT Seq ID No.94 KKRPQRRYSNVPRRRQRRKKRG opMLC-S20-RvTAT Seq ID No.95 QIAKRRRLSSLRARRRQRRKKRG rSP6-S235-RvTAT Seq ID No.96 NLSRRLKVTGDLRRRQRRKKRG BECN1-T199-RvTAT
- the fusion polypeptide can be expressed by an expression system and then purified, which is a mature technology in the art, and will not be repeated here.
- the fusion polypeptide provided by the present invention is a small molecule polypeptide, and chemical synthesis method is also an ideal choice.
- the fusion polypeptide used for the subsequent test of the present invention was synthesized by GenScript Biotechnology Co., Ltd. (GenScript, China) using the solid phase peptide synthesis (SPPS) method of Fmoc chemistry.
- SPPS solid phase peptide synthesis
- the SPPS method is to add amino acid sequences to the resin to construct peptide chains.
- the Fmoc group is deprotected at the N-terminus, and then the side chain protecting group is deprotected, and then the peptide is cleaved from the resin; after preparative reversed phase high performance liquid chromatography , RP-HPLC) purification, the purification solvent is acetonitrile + deionized water, 0.1% trifluoroacetic acid (TFA) was added as a buffer, and gradient elution was performed.
- TFA trifluoroacetic acid
- the purity was confirmed to be greater than 95% by analytical RP-HPLC, and its molecular weight was determined by Electrospray Ionization Mass Spectrometry (ESI-MS) to determine the composition ( Figure 1).
- the content of peptides was determined by nitrogen determination with Vario MICRO Element Analyzer. The calculation of the actual amount of polypeptide is weighing * purity * content.
- the fusion polypeptides in this paper are all white powders, stored at -20 °C in the dark, completely soluble in water, and made into 200 ⁇ M stock solutions in sterile water or normal saline, and according to the injury model, in the concentration range of 0.1 to 2 ⁇ M assessment within.
- Neurobasal Medium Thermo Fisher Scientific Gibco 10888022
- DMEM medium Dulbecco's Modified Eagle Medium: Thermo Fisher Scientific 10569077
- HT22 mouse hippocampal neuron cell line cells were cultured and maintained in DMEM medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 ⁇ g/ml streptomycin. Cells were maintained at 37°C in 5% CO2 /95% air.
- 6 x 10 3 cells/well HT22 cells were seeded in 96-well plates and cultured at 37°C in a CO 2 incubator for 24 hours, and the medium was changed to supplemented with 2% B27 (B-27 TM) . Plus Supplement (50X), Neurobasal Medium, and various concentrations of test drugs, and HT22 cells were exposed to 6 mM glutamate for further continuous culture in a 37°C, CO incubator for 24 Hour. Cell viability was determined using the MTT colorimetric method.
- Water-soluble yellow dye MTT reagent (final concentration 0.5 mg/ml) was added to each well and incubated at 37°C. After 4 hours, the incubation medium was removed, 100 ⁇ l of dimethyl sulfoxide (DMSO) was added, and after dissolving at room temperature for 30 minutes, the absorbance of the formazan (Formazan) solution was measured spectrophotometrically at 570 nm.
- DMSO dimethyl sulfoxide
- MTT absorbance data were converted to reflect proportional cell viability relative to untreated and treated controls, with untreated controls considered 100% viability.
- HT22 cells were exposed to 6 mM glutamate and simultaneously added with different concentrations of RvTAT-PKD-S205 peptide, and cell viability was measured by MTT colorimetry after 24 hours: 100nM, 200nM, 400nM and 1600nM of RvTAT-PKD-S205 peptide Correspondingly, cell death was reduced by 11%, 22%, 32% and 24%. 400nM and 1600nM showed significant neuroprotective efficacy, but the neuroprotective efficacy of 1600nM was reduced.
- the experimental results show that the chimeric peptide RvTAT-PKD-S205 provided by the present invention has a significant concentration-dependent neuroprotective effect in the glutamate cell apoptosis model, and shows that 400nM is the best dose of RvTAT-PKD-S205 polypeptide. drug concentration ( Figure 2).
- Dulbecco's Modified Eagle's Medium (DMEM): Thermo Fisher Scientific 30030
- EBSS Earle's Balanced Salt Solution
- cortical neurons Primary cultures of cortical neurons (Wenxiang Fan, Xiang Li, LiangliangHuang, ShuchengHe, ZhichengXie, YuxinFu, WeirongFang, YunmanLi) were made at embryonic days 15 to 18 in Sprague-Dawley (SD) rats.
- S-oxiracetam ameliorates ischemic stroke induced neuronal apoptosis through up-regulating ⁇ 7 nAChR and PI3K/ Akt/GSK3 ⁇ signal pathway in rats Neurochemistry International Volume 115, May 2018, Pages 50-60 https://doi.org/10.1016/j.neuint.2018.01.008),
- the specifics are as follows: the cerebral cortex was dissociated in Dulbecco's modified Eagle's medium (DMEM), and after 5 min digestion at 37°C with 0.25% trypsinization, the digestion was terminated by adding fetal bovine serum (final concentration 10%) stage. It was then obtained by repeated pipetting through a Pasteur pipette after centrifugation at 500 xg for 5 minutes.
- DMEM Dulbecco's modified Eagle's medium
- Cells were dissociated in N Neurobasal medium supplemented with 2% B27 (v/v), 1 mM glutamine, 50 units/ml penicillin and 50 units/ml streptomycin. Cells were plated in 24-well plates (coated with 0.1 mg/mL poly-D-lysine) at a density of 1.5 x 105 cells per well, followed by medium changes every 3 days. The cultures were maintained for 7 days at 37°C in a humidified incubator with 5% CO2/95% air.
- Oxygen glucose deprivation experiments were performed according to previously established methods (J.Huang, ND Kodithuwakku, W.He, Y.Zhou, W.Fan, W.Fang, G.He, Q.Wu, S.Chu, Y.Li
- the neuroprotective effect of a novel agent N2 on rat cerebral ischemia associated with the activation of PI3K/Akt signaling pathway Neuropharmacology, 95(2015), pp.12-21) with some modifications to mimic in vivo ischemia and reperfusion (Ischemia/Reperfusion , I/R) injury as follows: before exposure to OGD, in the primary culture of the drug experimental group, add different concentrations of test drugs to the neural basal medium, and place them in a CO 2 incubator at 37 °C for 30 After 10 minutes, all primary cultures had media removed and the OGD group replaced with a sugar-free Earle's Balanced Salt Solution (EBSS) solution with or without medicated hyposulfite (Na 2 S 2 O
- the primary neurons were added with two progressive concentrations of RvTAT-PKD-S205 polypeptide 30 minutes before OGD, and then sodium dithionite was added to induce hypoxia and hypoglycemia in neurons for 60 minutes. Oxygenated incubation conditions for 20 hours, and then cell viability was measured by MTT colorimetry.
- rat middle cerebral artery occlusion/reperfusion transient Middle Cerebral Artery Occlusion/Reperfusion, tMCAO/R stroke model was established. The details are as follows: 220-250g male Sprague-Dawley rats can eat and drink freely, and in a constant environment conditions (12/12 hour light/dark cycle). However, the rats were fasted the night before the operation and had free access to water. During the operation, the rats were anesthetized with chloral hydrate (300 mg/kg, intraperitoneal injection), and then the rats were supine and fixed on the heating pad on the operating table. During surgical procedures, body temperature was continuously monitored using a rectal probe and maintained at 36.5–37.0°C.
- the surgical area was disinfected with povidone-iodine or 70% alcohol, a midline incision was made in the neck, and the soft tissue on the trachea was gently pulled apart with a retractor.
- the common carotid artery (CCA), external carotid artery (ECA) and internal carotid artery (ICA) were carefully isolated from the vagus nerve.
- the ECA was ligated distally, the pterygoid artery was tightly connected to the ICA, and then one microvascular clip was placed on the ICA and the other on the CCA to prevent blood backflow.
- the ligated ECA was cauterized to form a stump, a 4-0 nylon suture with rounded ends was inserted through the ECA stump into the CCA junction, and the microvascular clip placed in the ICA was removed to allow the insertion of the suture.
- the pegs were carefully inserted from the CCA knot into the MCA for 18 to 20 mm, after which the pegs were secured in two positions (on the bottom of the ECA stump and on the ICA). After 90 minutes of occlusion, the suture was carefully pulled out, the ECA incision was tied tightly, the microvascular clip placed in the CCA was removed, and after blood reperfusion was confirmed, the neck skin was sutured.
- topical lidocaine gel was applied to the surgical incision area, and animals were subcutaneously injected with 1.0 mL of normal saline for hydration after surgery. Sham-operated animals underwent the same procedure but without arterial sutures to block blood flow. 4.5 hours after tMCAO, a dose of 3.5 mg/2 ml/kg of test drug or sterile saline was administered intravenously within 3 minutes. The body temperature of the mice during recovery was maintained at 37°C with a heat lamp.
- RvTAT-PKD-S205 Treatment with RvTAT-PKD-S205 resulted in a statistically significant reduction in total cerebral infarct volume (approximately 60%) compared to control stroke volume (Fig. 5B,C). This result demonstrates that RvTAT-PKD-S205 can play a role in reducing brain damage caused by ischemic stroke in vivo.
- the duration of the rat's ability to stay on the rotarod in 180 seconds was measured, and the test was over if the animal dropped the rotarod or grabbed the rotarod and made 2 consecutive turns without trying to re-up the rotarod .
- the average duration of 3 gyroscope tests was recorded the day before tMCAO/R surgery. Rotameter tests were performed on days 3, 5, and 7 after tMCAO/R (or after sham surgery), three consecutive measurements were taken daily, and the average of the three was taken, and animals were allowed to rest between each test 15 minutes.
- RvTAT-PKD1-S205 peptide treatment significantly improved the motor performance of tMCAO/R rats, and rod holding time increased by 70% and 75%, respectively, at 5 and 7 days after tMCAO/R compared with the untreated control group .
- the results showed that RvTAT-PKD-S205 could significantly improve the neurobehavioral symptoms of ischemic stroke-induced rats.
- mice C57BL/6 male mice weighing 20–30 g (6–7 weeks old) with free access to food and water and housed under constant environmental conditions (12/12 hour light/dark cycle). Mice were anesthetized with an intraperitoneal injection of 10% chloral hydrate (350 mg/kg), then placed on a heating pad to maintain rectal temperature at 37°C, and BCCAO procedures were performed according to previously established methods. The shaved ventral neck region of mice was washed with povidone-iodine followed by 70% ethanol. A small midline skin incision is made in the neck. The medial sternocleidomastoid muscle was dissected and carefully dissected from the vagus nerve and connective tissue to expose the common carotid artery.
- 10% chloral hydrate 350 mg/kg
- BCCAO procedures were performed according to previously established methods.
- the shaved ventral neck region of mice was washed with povidone-iodine followed by 70% ethanol. A small midline skin incision is made in the
- Atraumatic vascular clamps were applied to occlude each artery for 20 minutes. The clips were removed and blood flow was restored for 10 minutes. The bilateral common carotid arteries were then occluded for another 20 minutes, and perfusion was resumed for another 24 hours. 3 hours after tBCCAO, 7 mg/2 ml/kg of test drug was injected intravenously over 3 minutes. During recovery, the mouse's body temperature was maintained at 37°C with a heat lamp. Sham-operated control animals underwent all surgical procedures except for bilateral common carotid artery occlusion.
- the Y-maze apparatus consists of three arms (A, B, and C) angled at 120° and connected by a central zone (CZ).
- a grid made of stainless steel
- Any of these three arms can be set as the starting area by the computer, which is defined as the non-safe area after the start of the experiment.
- the remaining two arms were randomly divided into a safe area without foot shock (current stimulus) and a non-safe area with foot shock by the Y-maze video tracking and analysis system.
- mice with bilateral common carotid artery transient occlusion and reperfusion tBCCAO/R
- tBCCAO/R transient bilateral common carotid artery occlusion and reperfusion
- RvTAT-PKD-S205 peptide and normal saline were injected into the tail vein 3 hours after modeling. Learning and memory skills were measured by the Y-maze passive avoidance task 24 hours after tBCCAO/R modeling (Fig. 6A).
- mice were placed in the starting area to start the experiment.
- Current stimulation of a predetermined intensity (0.05-0.8 mA) was applied, and the animals had to escape into an adjacent safe area to avoid foot shocks for 30 seconds.
- the animal was then placed in the starting position for subsequent testing.
- the number of escapes to the safe zone is recorded, any escape to a non-safe zone is considered an error.
- the ten tests were averaged to calculate the average escape percentage. Clean equipment thoroughly with disinfectant and/or alcohol spray between animal changes.
- mice in the RvTAT-PKD-S205-treated group significantly increased the percentage of successful avoidance compared to the saline-treated group, RvTAT-PKD
- the -S205 peptide ameliorated the tBCCAO/R-induced decrease in the memory index, with a 30% increase in the memory index in the treated group compared to the untreated group (Fig. 6B).
- MDA is one of the important products of lipid peroxidation, and the degree of lipid oxidation is determined by measuring the level of MDA.
- MDA levels in tissues were estimated by the Thiobarbituric acid (TBA) method. After the behavioral tests described above, the mice were decapitated and brain tissue was removed. Brain tissue was homogenized in ice-cold saline. The lysates were centrifuged at 3500 rpm for 10 min at 4°C and the supernatant was collected, and the MDA content was determined using the MDA TBA kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer's protocol. Results were evaluated from a standard curve and calculated as nM/mg protein.
- Stroke-induced brain edema was assessed by wet-dry method 24 hours after tBCCAO/R in mice, wet weight was determined immediately after brain dissection, and dry weight was determined by drying the tissue at 55°C to constant weight over 24 hours. The percentage of brain water content was calculated as (wet weight-dry weight)/wet weight*100.
- the concentration of MDA in brain tissue was used to assess the severity of neuronal ischemic injury. Compared with tBCCAO/R mice in the saline control group, the MDA concentration in the brain of tBCCAO/R mice treated with RvTAT-PKD-S205 was reduced by 55%, and the growth of MDA after neuronal ischemic injury was significantly inhibited (Figure 6C). ). Increased brain edema was assessed by measuring brain water content, which was significantly reduced by 8.5% after RvTAT-PKD-S205 treatment compared to the saline control group ( Figure 6D). The results showed that RvTAT-PKD-S205 attenuated brain edema and oxidative stress injury in the experimental tBCCAO/R model.
- fusion polypeptides containing other interfering peptides listed in Table 1 were synthesized and evaluated on HT22 cell line glutamate challenge model and primary neuron culture OGD model.
- the present invention provides RvTAT-PKD-S205 (the N-terminal of SEQ ID NO.1 is connected with a penetrating peptide) and its homologous interfering peptide (the N-terminal or C of SEQ ID NO.23 to SEQ ID NO.39 in Table 1) peptide attached) provided significant neuroprotection, reducing cortical neuronal death by 12% and 18% in a concentration-dependent manner at 300 and 1000 nM, respectively;
- RvTAT-ZIPK-T299 (the N-terminal of SEQ ID NO. 2 is connected to the penetrating peptide) and its homologous interfering peptide (the N-terminal or C of SEQ ID NO. 8 to SEQ ID NO. 22 in Table 1 is connected to the penetrating peptide) peptide) also effectively reduced cortical neuron death by 12% at 1000 nM;
- RvTAT-opMLC-S20 (the N-terminal of SEQ ID NO. 4 is connected to a penetrating peptide) peptide did not significantly increase the survival rate of neurons, with RvTAT-PKD-S205, RvTAT-ZIPK-T299 and RvTAT-opMLC-S20 As an example, the results of the neuroprotection comparison experiments are shown in Figure 3.
- RvTAT-PKD-S205 (the N-terminal of SEQ ID NO. 1 is connected to a penetrating peptide) and its homologous interfering peptide (SEQ ID NO. 23 to SEQ ID NO.
- the N-terminal or C of 39 is connected to the penetrating peptide
- RvTAT-ZIPK-T299 (the N-terminal of SEQ ID NO.2 is connected to the penetrating peptide) and its homologous interfering peptide (SEQ ID NO.2-SEQ ID NO.2 in Table 1)
- the N-terminal or C-linked penetrating peptide of ID NO.22 is a more potential neuroprotective peptide.
- Both types of peptides can reduce HT22 cell death by an average of about 33%, followed by RvTAT-rSP6-S235 (SEQ ID NO.
- the N-terminal of 3 is connected with a penetrating peptide) and its homologous interfering peptide (the N-terminal or C of SEQ ID NO.40 to SEQ ID NO.54 in Table 1 is connected with a penetrating peptide), RvTAT-opMLC-S20 (SEQ ID NO.
- the N-terminus of ID NO.4 is connected with a penetrating peptide) and RvTAT-BECN1-T199 (the N-terminus of SEQ ID NO.5 is connected with a penetrating peptide) and its homologous interfering peptide (SEQ ID NO.6- in Table 1- 7 N-terminal or C-linked penetrating peptide) at 400 nM reduced HT22 cell death by an average of about 29%, 25%, and 21%, respectively; with RvTAT-PKD-S205, RvTAT-rSP6-S235, RvTAT-opMLC-S20 and RvTAT-BECN1-T199 is an example, and the comparison results are shown in Figure 4.
- DAPK1 Death Associated Protein Kinase 1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
序列编号 | 融合多肽的氨基酸序列 | 序列名称 |
Seq ID No.87 | RRRQRRKKRGSGVRRRRLSNVSL | RvTAT-PKD-S205 |
Seq ID No.88 | RRRQRRKKRGRKPERRRLKTTRL | RvTAT-ZIPK-T299 |
Seq ID No.89 | RRRQRRKKRGKKRPQRRYSNVP | RvTAT-opMLC-S20 |
Seq ID No.90 | RRRQRRKKRGQIAKRRRLSSLRA | RvTAT-rSP6-S235 |
Seq ID No.91 | RRRQRRKKRGNLSRRLKVTGDL | RvTAT-BECN1-T199 |
Seq ID No.92 | SGVRRRRLSNVSLRRRQRRKKRG | PKD-S205-RvTAT |
Seq ID No.93 | RKPERRRLKTTRLRRRQRRKKRG | ZIPK-T299-RvTAT |
Seq ID No.94 | KKRPQRRYSNVPRRRQRRKKRG | opMLC-S20-RvTAT |
Seq ID No.95 | QIAKRRRLSSLRARRRQRRKKRG | rSP6-S235-RvTAT |
Seq ID No.96 | NLSRRLKVTGDLRRRQRRKKRG | BECN1-T199-RvTAT |
Claims (23)
- 一种DAPK1磷酸化底物的人工小分子干扰肽,其特征在于,其氨基酸序列如SEQ ID NO.1,SEQ ID NO.2、SEQ ID NO.3、SEQ ID NO.4或SEQ ID NO.5所示。
- 一种DAPK1磷酸化底物的人工小分子干扰肽,其特征在于,其具有以下(A)或(B)所示的氨基酸基序:(A)XXX(R/K)(R/K)(R/K)(R/K)X2(S/T/A)X1 XXX;(B)XXX(R/K)(R/K)(R/K)X2(R/K)(S/T/A)X1 XXX其中每个X可以独立地选自任何氨基酸或无氨基酸;X1为极性氨基酸,选自天冬酰胺(N),半胱氨酸(C),谷氨酰胺(Q),丝氨酸(S)或苏氨酸(T)X 2为非极性氨基酸,选自丙氨酸(A),异亮氨酸(I),亮氨酸(L),甲硫氨酸(M)和缬氨酸(V);其中R/K指该位置上可任意地采用精氨酸(R)或赖氨酸(K);其中S/T/A指该位置上可任意地采用丝氨酸(S)、苏氨酸(T)或丙氨酸(A);优选地,人工小分子干扰肽的氨基酸序列还与SEQ ID NO.1,SEQ ID NO.2或SEQ ID NO.3所示的氨基酸序列中的至少一个相比差异不多于2个氨基酸,即具有至少85%的一致性。
- 根据权利要求2所述的人工小分子干扰肽,其氨基酸序列如SEQ ID NO.6-54任一所示。
- 根据权利要求2所述的人工小分子干扰模拟肽,其结构为订书肽或环肽,如:首尾成环(酰胺键),侧链成环,硫酯键成环,内酯键成环,Se-Cys和Se-Cys间氧化成环,或二硫键的环肽。
- 权利要求1-3任一所述的人工小分子干扰肽的反向多肽,即与人工小分子干扰肽相比,肽链中氨基酸的顺序改为从C端到N端。
- 权利要求1-3任一所述的人工小分子干扰肽的D型逆反肽,所述D型逆反肽与所述人工小分子干扰肽相比,是所述人工小分子干扰肽中的每个L-氨基酸残基被其对应的D型氨基酸替换,其氨基酸序列是反转的同时其侧链的原始空间方向和手性与所述人工小分子干扰肽相同,即保持与所述人工小分子干扰肽相似的侧链拓扑结构。
- 权利要求1-3任一所述的人工小分子干扰肽的衍生肽,其特征在于,是对权利要求1-3任一所述的人工小分子干扰肽中的任一个或多个氨基酸替换成其对应的D型氨基酸或高氨基酸而得。
- 一种多聚肽,其特征在于,是两条以上小分子肽以同向并联方式聚合构成,其中的每个小分子肽的C端游离,所有小分子肽的N端聚集在一起用于与递送载体连接;所述小分子肽选自权利要求1-3任一所述的人工小分子干扰肽,权利要求5所述的反向多肽、权利要求6所述的D型逆反肽,或权利要求7所述的衍生肽。
- 一种融合多肽,其特征在于,是在小分子肽的N末端或C末端融合一种或多种递送载体构成;所述小分子肽选自权利要求1-3任一所述的人工小分子干扰肽,权利要求5所述的反向多肽、权利要求6所述的D型逆反肽,或权利要求7所述的衍生肽。
- 根据权利要求8所述的多聚肽或权利要求9所述的融合多肽,其特征在于,所述递送载体选自穿膜肽、配体,受体蛋白转导结构域(PTD)、抗体或高分子聚合物;所述穿膜肽选自阳离子型细胞穿膜肽、两亲型细胞穿膜肽、疏水型细胞穿膜肽或合成型细胞穿膜肽;所述高分子聚合物选自聚乙二醇(PEG)、聚乳酸,聚Lactide-co-Glycolide,聚乙醇酸,聚己酸内酯,聚环氧乙烷,聚二噁烷酮,聚丙烯富马酯,三亚甲基碳酸酯,聚酯酰胺环氧乙烷,酯酰胺,β-羟基苯丙酸酯,α-羟基酸,聚羟基烷酸,多聚羟基丁酸,聚酰亚胺碳酸盐,聚亚安酯,聚酸酐,透明质酸,甲壳胺,纤维素,明胶,胶原蛋白。
- 根据权利要求10所述的融合多肽,其特征在于,所述阳离子型细胞穿膜肽选自Seq.ID No.55至Seq.ID No.72所示的氨基酸序列组成的组;所述两亲型细胞穿膜肽选自Seq.ID No.73至Seq.ID No.81所示的氨基酸序列组成的组;所述疏水型细胞穿膜肽选自Seq.ID No.82至Seq.ID No.85所示的氨基酸序列组成的组;所述合成型细胞穿膜肽具有Seq.ID No.86所示的氨基酸序列。
- 根据权利要求11所述的融合多肽,其特征在于,所述人工小分子干扰肽具有SEQ ID NO.1-3、SEQ ID NO.6-54任一所示的氨基酸序列;所述穿膜肽具有Seq.ID No.55-Seq.ID No.86任一所示的氨基酸序列。
- 根据权利要求10所述的融合多肽,其特征在于,其氨基酸序列如Seq.ID No.87-Seq.ID No.96任一所示。
- 一种人工制备的核酸分子,其特征在于,其编码小分子多肽,所述小分子肽选自权利要求1-3任一所述的人工小分子干扰肽,权利要求5所述的反向多肽。
- 一种表达载体,其特征在于,装载有14所述的核酸分子。
- 一种表达系统,其特征在于,为细胞系或无细胞体系表达系统,含有权利要求15所述的载体。
- 一种表达产物,其特征在于,由权利要求14所述的表达系统表达,其主要成分为小分子多肽;所述小分子肽选自权利要求1-3任一所述的人工小分子干扰肽,权利要求5所述的反向多肽。
- 一种药物,其特征在于,含有多肽分子以及药学可接受的杂质、辅料、溶剂、保护剂、佐剂、载体和/或赋形剂;其中所述多肽分子为:(1)权利要求1-3任一所述的人工小分子干扰肽,权利要求5所述的反向多肽、权利要求6所述的D逆反肽,或权利要求7所述的衍生肽或(2)小分子肽的修饰产物,所述小分子肽选自权利要求1-3任一所述的人工小分子干扰肽,权利要求5所述的反向多肽、权利要求6所述的D型逆反肽,或权利要求7所述的衍生肽;所述修饰指以下一种或多种:N末端、C末端修饰、标记、环化、脂化、N-甲基化、豆蔻酰化和棕榈酰化、糖基化、生物素化、PEG修饰、荧光标记。
- 根据权利要求18所述的药物,其特征在于,剂型为:吸入气雾剂、口服剂、静脉内给药、动脉内给药、颅内给药、腹膜内给药、鼻内给药、肌肉内给药、皮下给药、滑膜(腔)内给药、胸骨内给药,脊椎内给药制剂。
- 小分子肽的的制药用途,其特征在于,所述小分子肽选自权利要求1-3任一所述的人工小分子干扰肽,权利要求5所述的反向多肽、权利要求6所述的D型逆反肽,或权利要求7所述的衍生肽;所述制药用途是指用于制备治疗或预防与兴奋性氨基酸毒性机制相关的疾病的药物,所述疾病包括但不限于脑卒中、创伤性脑损伤、脊髓损伤、新生儿缺氧缺血性脑病、神经系统退行性疾病、抑郁症、自闭症;所述神经系统退行性疾病指多发性硬化症,阿尔茨海默氏病,肌萎缩侧索硬化,帕金森病或亨廷顿病。
- 小分子肽的的制药用途,其特征在于,所述小分子肽选自权利要求1-3任一所述的人工小分子干扰肽,权利要求5所述的反向多肽、权利要求6所述的D型逆反肽,或权利要求7所述的衍生肽;所述制药用途是指用于制备治疗或预防与DAPK1-PKD1通路相关的生理异常的药物,所述疾病包括但不限于脑卒中、创伤性脑损伤、脊髓损伤、新生儿缺氧缺血性脑病、神经系统退行性疾病、抑郁症、自闭症;所述神经系统退行性疾病指多发性硬化症,阿尔茨海默氏病,肌萎缩侧索硬化,帕金森病或亨廷顿病。
- 一种药物组合,其特征在于,包含权利要求18或19所述的药物以及抗凝血药或抗血小板药;优选,权利要求18或19所述的药物以及所述抗凝血药或抗血小板药被按照单次剂量、单日剂量或疗程剂量为单位组合包装在一起;其中所述抗凝血药是指醋硝香豆素、4-羟基-3-(1,2,3,4-四氢-1-萘基)香豆素(杀鼠醚)、双香豆素、双香豆素乙酯、苯丙香豆素、苄丙酮香豆素、二苯茚酮、苯茚二酮、噻氯香豆醇、贝米肝素、舍托肝素钠、达肝素、依诺肝素、那屈肝素、帕肝素、瑞维肝素、亭扎肝素、磺达肝素、依达肝素、达那肝素、舒洛地特、硫酸皮肤素、阿哌沙班、贝曲西班、依杜沙班、奥米沙班、利伐沙班、水蛭素、比伐卢定、重组水蛭素、地西卢定水蛭素、阿加曲班、达比加群酯、美拉加群、希美加群、去纤维蛋白多核苷酸、抗凝血酶Ⅲ、肝素、可迈丁锭、达比加群酯、艾乐妥、依度沙班、依诺肝素、磺达肝素、重组组织型纤溶酶原激活剂、组织型纤溶酶原激活剂、阿替普酶、瑞替普酶、替奈普酶、尿激酶、沙芦普酶、链激酶、阿尼普酶、孟替普酶、安克洛酶、溶纤维蛋白酵素、纤维蛋白酶,或其组合物;所述抗血小板药是指氯吡格雷、替格瑞洛、普拉格雷、双嘧达莫、西洛他唑、噻氯匹啶、埃替非巴肽、阿司匹林、阿昔单抗、替罗非班、贝前列素、环前列腺素、伊洛前列素、曲前列环素、阿洛普令、卡巴匹林钙、吲哚布芬、三氟醋柳酸、吡考他胺、特鲁曲班、氯克罗孟、地他唑,或其组合物。
- 小分子肽的的疾病治疗用途,其特征在于,所述小分子肽选自权利要求1-3任一所述的人工小分子干扰肽,权利要求5所述的反向多肽、权利要求6所述的D型逆反肽,或权利要求7所述的衍生肽;其中给药量是从0.001mg/kg体重至50mg/kg;在此所述的小分子肽的浓度可以广泛地改变,并且根据所选择的给药方式及受试者的体重,年龄,性别等进行选择;优选的剂量范围为剂量从0.01mg/kg体重至50mg/kg;进一步优选的剂量范围为剂量从0.1mg/kg体重至10mg/kg;或者改变剂量范围以便优化一个受试者或一组受试者中的治疗方;所述疾病包括但不限于脑卒中、创伤性脑损伤、脊髓损伤、新生儿缺氧缺血性脑病、神经系统退行性疾病、抑郁症、自闭症;所述神经系统退行性疾病指多发性硬化症,阿尔茨海默氏病,肌萎缩侧索硬化,帕金森病或亨廷顿病。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023548936A JP2024506919A (ja) | 2021-02-10 | 2022-02-09 | Dapk1リン酸化基質の人工低分子干渉ペプチド及びその製薬上の用途 |
EP22752258.8A EP4293037A4 (en) | 2021-02-10 | 2022-02-09 | SMALL MOLECULE ARTIFICIAL INTERFERING PEPTIDE OF A PHOSPHORYLATED SUBSTRATE OF DAPK1 AND ITS PHARMACEUTICAL USE |
US18/447,364 US20240034752A1 (en) | 2021-02-10 | 2023-08-10 | Artificial short interfering peptide for the phosphorylation substrate of dapk1 and its pharmaceutical applications |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110183968.2 | 2021-02-10 | ||
CN202110183968 | 2021-02-10 | ||
CN202210110300.X | 2022-01-29 | ||
CN202210110300.XA CN114605497B (zh) | 2021-02-10 | 2022-01-29 | 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/447,364 Continuation-In-Part US20240034752A1 (en) | 2021-02-10 | 2023-08-10 | Artificial short interfering peptide for the phosphorylation substrate of dapk1 and its pharmaceutical applications |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022171098A1 true WO2022171098A1 (zh) | 2022-08-18 |
Family
ID=81859961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/075581 WO2022171098A1 (zh) | 2021-02-10 | 2022-02-09 | 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240034752A1 (zh) |
EP (1) | EP4293037A4 (zh) |
JP (1) | JP2024506919A (zh) |
CN (1) | CN114605497B (zh) |
WO (1) | WO2022171098A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050003450A1 (en) * | 1998-09-04 | 2005-01-06 | John Rush | Immunoaffinity isolation of modified peptides from complex mixtures |
US20070059787A1 (en) * | 2003-07-29 | 2007-03-15 | Invitrogen Corporation | Kinase and phosphatase assays |
WO2008008225A2 (en) | 2006-07-10 | 2008-01-17 | Sigma Industries, Llc | Retractable lifeline safety device |
CN101277611A (zh) * | 2005-09-30 | 2008-10-01 | Kai医药有限公司 | 药物制剂 |
US20090149389A1 (en) * | 2007-01-10 | 2009-06-11 | Purdue Research Foundation | Kinase Inhibitors And Uses Thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0625659D0 (en) * | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
WO2012009447A2 (en) * | 2010-07-13 | 2012-01-19 | University Of Rochester | THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
GB2527364A (en) * | 2014-06-20 | 2015-12-23 | Imp Innovations Ltd | Treatment |
AU2017321313A1 (en) * | 2016-08-29 | 2019-03-21 | Board Of Regents, The University Of Texas System | Inhibitors of dual leucine ziper (DLK) kinase for the treatment of disease |
-
2022
- 2022-01-29 CN CN202210110300.XA patent/CN114605497B/zh active Active
- 2022-02-09 EP EP22752258.8A patent/EP4293037A4/en active Pending
- 2022-02-09 JP JP2023548936A patent/JP2024506919A/ja active Pending
- 2022-02-09 WO PCT/CN2022/075581 patent/WO2022171098A1/zh active Application Filing
-
2023
- 2023-08-10 US US18/447,364 patent/US20240034752A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050003450A1 (en) * | 1998-09-04 | 2005-01-06 | John Rush | Immunoaffinity isolation of modified peptides from complex mixtures |
US20070059787A1 (en) * | 2003-07-29 | 2007-03-15 | Invitrogen Corporation | Kinase and phosphatase assays |
CN101277611A (zh) * | 2005-09-30 | 2008-10-01 | Kai医药有限公司 | 药物制剂 |
WO2008008225A2 (en) | 2006-07-10 | 2008-01-17 | Sigma Industries, Llc | Retractable lifeline safety device |
US20090149389A1 (en) * | 2007-01-10 | 2009-06-11 | Purdue Research Foundation | Kinase Inhibitors And Uses Thereof |
Non-Patent Citations (27)
Title |
---|
A EISENBERG-LERERA KIMCHI: "DAP kinase regulates JNK signalling by binding and activating protein kinase D under oxidative stress", CELL DEATH & DIFFERENTIATION, vol. 14, 2007, pages 1908 - 15 |
A EISENBERG-LERNERA KIMCHI: "DAP kinase regulates JNK signalling by binding and activating protein kinase D under oxidative stress", CELL DEATH DIFFER, vol. 14, 2007, pages 1908 - 15 |
A SCHUMACHERA VELENTZAD WATTERSONJ DRESIOS: "Death-Associated Protein Kinase Phosphorylates Mammalian Ribosomal Protein S6 and educes Protein Synthesis", BIOCHEMISTRY, vol. 45, 2006, pages 13614 - 21 |
A VELENTZA, A SCHUMACHER, C WEISS, M EGLI, D WATTERSON: "A protein kinase associated with apoptosis and tumor Suppression: structure, activity, and discovery of peptide substrates", J BIOL CHEM, vol. 276, 2001, pages 38945 - 65 |
ADVANCES IN PHYSIOLOGY EDUCATION, vol. 42, no. 5, 2011 |
BIALIK SHANI, BERISSI HANNA, KIMCHI ADI: "A High Throughput Proteomics Screen Identifies Novel Substrates of Death-associated Protein Kinase", MOLECULAR & CELLULAR PROTEOMICS, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 7, no. 6, 1 June 2008 (2008-06-01), US , pages 1089 - 1098, XP055958256, ISSN: 1535-9476, DOI: 10.1074/mcp.M700579-MCP200 * |
CUI H., ET AL: "PDZ Protein Interactions Underlying NMDA Receptor-Mediated Excitotoxicity and Neuroprotection by PSD-95 Inhibitors", THE JOURNAL OF NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, US, vol. 27, no. 37, 12 September 2007 (2007-09-12), US , pages 9901 - 9915, XP002581414, ISSN: 0270-6474, DOI: 10.1523/jneurosci.1464-07.2007 * |
EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 19, pages 1329 - 1333 |
EZALCKVAR, H BERISSI, L MIZRACHY ,Y IDELCHUK , I KOREN, M EISENSTEIN, H SABANAY, R. PINKAS-KRAMAISKI, A KIMCHI: "DAP-kinase phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy", EMBO REP, vol. 10, 2009, pages 285 - 92, XP002572466, DOI: 10.1038/embor.2008.246 |
FRASER JENNIFER A., HUPP TED R.: "Chemical Genetics Approach to Identify Peptide Ligands that Selectively Stimulate DAPK-1 Kinase Activity", BIOCHEMISTRY, vol. 46, no. 10, 1 March 2007 (2007-03-01), pages 2655 - 2673, XP055958258, ISSN: 0006-2960, DOI: 10.1021/bi061562j * |
G SHANIL MARASHD GOZUACIKS BIALIKL TEITELBAUMG SHOHATA KIMCHI: "Death-associated protein kinase phosphorylates ZIP kinase ,forming a unique kinase hierarchy to activate its cell death functions", MCB, vol. 24, 2004, pages 8611 - 26 |
H CUIA HAYASHIH SUNM BELMARESC COBEYT PHANJ SCHWEIZERM SALTERY WANGR TASKER: "PDZ Protein Interactions Underlying NMDA Receptor-Mediated Excitotoxicity and Neuroprotection by PSD-95 Inhibitors", J NEUROSCI, vol. 27, 2007, pages 9901 - 15, XP002581414, DOI: 10.1523/jneurosci.1464-07.2007 |
I YONEKURA, N KAWAHARA, H NAKATOMI, K FURUYA, T KIRINO: "A model of global cerebral ischemia in C57BL/6 mice", J CEREB BLOOD FLOW METAB, vol. 24, 2004, pages 151 - 8 |
J FRASER, T HUPP: "Chemical Genetics Approach to Identify Peptide Ligands that Selectively Stimulate DAPK-1 Kinase Activity.", BIOCHEMISTRY, vol. 46, 2007, pages 2655 - 73, XP055958258, DOI: 10.1021/bi061562j |
J HOWLS JONES, TRANSPORT, 2009 |
J. HUANGN.D. KODITHUWAKKUW. HEY. ZHOUW. FANW. FANGG. HEQ. WUS. CHUY. LI: "The neuroprotective effect of a novel agent N2 on rat cerebral ischemia associated with the activation of PI3K/Akt signaling pathway", NEUROPHARMACOLOGY, vol. 95, 2015, pages 12 - 21 |
L WANG, J LIU, Y YANG, B PENG, Y WANG: "The Prevention and Treatment of Stroke Still Face Huge Challenges-Brief Report on Stroke Prevention and Treatment in China", CHINESE CIRCULATION JOURNAL, vol. 34, 2018, pages 105 - 19 |
M RU, H LIU: "Association between Y-Maze Acquisition Learning and Major Histocompatibility Complex Class II Polymorphisms in Mice", BIOMED RES INT, 2018, pages 6381932 |
M SHAMLOO, L SORIANO, T WIELOCH, K NIKOLICH, R URFER, D OKSENBERG: "Protein kinase D specifically mediates apoptosis signal-regulating kinase 1-JNK signally induced by H202 but not tumor necrosis factor ", J BIOL CHEM, vol. 280, 2005, pages 19036 - 44 |
P SINGHP RAVANANP TALWAR: "Death Associated Protein Kinase 1 (DAPK1): A Regulator of Apoptosis and Autophagy", FRONT. MOL. NEUROSCI, vol. 9, 2016, pages 46 |
Q GUO, G ZHAO, F HAO, Y GUAN: "Effects of the TAT peptide orientation and relative location on the protein transduction efficiency", CHEM BIOL DRUG DES, vol. 79, 2012, pages 683 - 690, XP072378347, DOI: 10.1111/j.1747-0285.2011.01315.x |
S AHMED, Y HE, ANASSIEF, J XU, X XU, C HSU, F FARACI: "Effects of lipopolysaccharide priming on acute ischemic brain injury", STROKE, vol. 31, 2000, pages 193 - 9 |
S CHENY HUW FANGY LI: "Clematichinenoside Facilitates Recovery of Neurological and Motor Function in Rats after Cerebral Ischemic Injury through Inhibiting Notch/NF-xB Pathway", J STROKE CEREBROVASC DIS, vol. 28, 2019, pages 104288, XP085883146, DOI: 10.1016/j.jstrokecerebrovasdis.2019.07.004 |
S WANGX SHIH LIP PANGL PEIH SHENY LU: "DAPK1 Signaling Pathways in Stroke: from Mechanisms to Therapies Molecular", NEUROBIOLOGY, vol. 54, 2017, pages 4716 - 4722 |
W FAN, XLI, L HUANG, S HE, Z XIE, Y FU, W FANG, Y LI: "S-oxiracetam ameliorates ischemic stroke induced neuronal apoptosis through up-regulatinga7 nAChR and P13K/Akt/GSK30signal pathway in rats", NEUROCHEM INT, vol. 115, 2018, pages 50 - 60 |
WENXIANG FANXIANG LILIANGLIANG HUANGSHUCHENG HEZHICHENG XIEYUXIN FUWEIRONG FANGYUNMAN LI: "S-oxiracetam ameliorates ischemic stroke induced neuronal apoptosis through up-regulating a7nAChR and P13K/Akt/GSK30 signal pathway in rats", NEUROCHEMISTRY INTERNATIONAL, vol. 115, May 2018 (2018-05-01), pages 50 - 60 |
WENXIANG FANXIANG LILIANGLIANG HUANGSHUCHENG HEZHICHENGXIEYUXIN FUWEIRONG FANGYUNMAN LI: "S-oxira cetam ameliorates ischemic stroke induced neuronal apoptosis through up-regulatinga7nAChR and P13K/Akt/GSK3 0 signal pathway in rats", NEUROCHEMISTRY INTERNATIONAL, vol. 115, May 2018 (2018-05-01), pages 50 - 60, Retrieved from the Internet <URL:https://doi.rg/10.1016/j.neuint.2018.01.0081> |
Also Published As
Publication number | Publication date |
---|---|
EP4293037A1 (en) | 2023-12-20 |
JP2024506919A (ja) | 2024-02-15 |
EP4293037A4 (en) | 2024-09-25 |
CN114605497A (zh) | 2022-06-10 |
CN114605497B (zh) | 2023-04-28 |
US20240034752A1 (en) | 2024-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI638831B (zh) | 胜肽化合物 | |
EP2409988B1 (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins | |
US11279738B2 (en) | Treatment of ischemia | |
US20190270781A1 (en) | Treatment of ischemia | |
DK2707014T3 (en) | Dimeric high affinity inhibitors of PSD-95 and their use in the treatment of ischemic brain injury and pain | |
JP4812347B2 (ja) | 抗菌性ペプチド | |
US7745390B2 (en) | Antimicrobial peptides | |
KR20190101990A (ko) | 펩티드 wkdeagkplvk를 포함하는 조성물 | |
TW200916112A (en) | The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases | |
KR101865420B1 (ko) | 벡터적 이온 채널의 조절을 위한 유기화합물 | |
US20230174582A1 (en) | Vipr2 antagonist peptide | |
JP7002788B2 (ja) | ポリペプチドの薬学的に許容される塩およびその使用 | |
BRPI0720874B1 (pt) | composições compreendendo peptídeos bioativos curtos para modulação celular e imunológica | |
WO2022171098A1 (zh) | 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途 | |
US20140094415A1 (en) | High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain | |
US20190092816A9 (en) | Stapled peptides and uses thereof | |
CN112194730B (zh) | 一种多肽ti-16及其用途 | |
JP2003502295A (ja) | 脳由来神経栄養因子の小さな環状模擬体 | |
US10400009B2 (en) | β-sheet breaker peptide used for preventing and/or treating alzheimer's disease | |
AU2017222450A1 (en) | Peptide inhibitors of calcium channels | |
WO2023061487A1 (zh) | 一种抑制trpm8的多肽及其用途 | |
EP4011904A1 (en) | Masp inhibitory compounds and uses thereof | |
WO2022150362A1 (en) | Poly-arginine derivatives for enhancing brain-derived growth factor to mitigate neurological disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22752258 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023548936 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022752258 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022752258 Country of ref document: EP Effective date: 20230911 |